IL6 -174G/C

Interleukin-6: The Exercise Cytokine With a Double Edge

Interleukin-6 (IL-6) is one of the most versatile signalling molecules in the human
body. Produced by immune cells, fat tissue, and — critically — by working skeletal
muscle, it acts as both a pro-inflammatory cytokine | a signalling protein that
promotes inflammation as part of the immune response and an anti-inflammatory
myokine | a cytokine released by muscle fibres during contraction, with systemic
metabolic effects. The -174G/C promoter variant (rs1800795) sits 174 base pairs
upstream of the IL6 gene on chromosome 7 and directly controls how much IL-6 your
cells produce.

The Mechanism

The G allele at position -174 creates a promoter sequence with higher
transcriptional activity | the rate at which a gene is read and converted into
mRNA, which then becomes protein. In reporter gene assays, the G allele drives
roughly 2-fold higher IL6 transcription compared to the C allele. This difference
is mediated by a binding site for the transcription factor
NF-1 | Nuclear Factor 1, a transcription factor that represses IL6 expression
when bound to the -174C sequence: the C allele creates this repressive binding
site, while the G allele abolishes it, allowing uninhibited transcription.

The consequence is straightforward: GG homozygotes produce the most IL-6 at baseline
and under stress, CG heterozygotes produce intermediate amounts, and CC homozygotes
produce the least. After stimulation by
LPS | lipopolysaccharide, a bacterial endotoxin that triggers immune activation
or IL-1, the G allele construct shows a robust increase in expression while the
C allele construct remains largely unresponsive.

The Evidence

The -174G/C variant is one of the most studied cytokine polymorphisms, with
evidence spanning cardiovascular disease, diabetes, exercise physiology, and ageing.

Cardiovascular risk: A meta-analysis of 74 studies with 86,229 subjects |
Rodriguez-Perez et al. Interleukin 6 (rs1800795) gene polymorphism is associated
with cardiovascular diseases. EXCLI Journal, 2019
found the C allele associated with increased cardiovascular disease risk
(dominant model OR 1.12, 95% CI 1.07-1.18). The association was strongest for
coronary artery disease (homozygous OR 1.50) and in Chinese populations
(allelic OR 1.36).

Exercise-induced muscle damage: Yamin et al. | IL6 (-174) and TNFA (-308)
promoter polymorphisms are associated with systemic creatine kinase response to
eccentric exercise. Eur J Appl Physiol, 2008
demonstrated that CC homozygotes had a greater than 3-fold increased risk of
massive creatine kinase | an enzyme released from damaged muscle fibres; elevated
CK after exercise is a marker of muscle damage (CK) response following
eccentric exercise. Paradoxically, despite producing less IL-6 at baseline, the
CC genotype appears to mount a more exaggerated muscle damage response.

Power athlete association: Ruiz et al. | The -174 G/C polymorphism of the IL6
gene is associated with elite power performance. J Sci Med Sport,
2010 found the GG genotype
overrepresented among elite power athletes (sprinters, jumpers, throwers) with
an OR of 2.47 compared to controls, suggesting the higher inflammatory response
may benefit explosive performance.

Diabetes: A comprehensive meta-analysis of 42,150 participants |
IL-6 gene rs1800795 polymorphism and diabetes mellitus. Diabetol Metab Syndr,
2022 found the G allele associated
with decreased type 2 diabetes risk in some populations, while the C allele
showed a protective effect against fasting hyperglycaemia.

Glucose metabolism: A joint analysis of 17 studies | Huth et al. Joint analysis
of individual participants' data from 17 studies on the association of the IL6
variant -174G>C. Ann Med, 2009
found C-allele carriers had significantly lower fasting glucose
(-0.091 mmol/L, P=0.014).

Practical Implications

The functional consequence of this variant — higher or lower IL-6 production —
has different implications depending on context:

For exercise recovery, GG carriers mount a stronger inflammatory response to
training, which may support adaptation for power sports but also means managing
recovery is important. CC carriers, despite lower baseline IL-6, show elevated
muscle damage markers after eccentric exercise and may need longer recovery
between intense sessions.

For cardiovascular health, the C allele carries modestly increased risk,
making anti-inflammatory lifestyle measures and regular monitoring more relevant
for CC and CG individuals.

For metabolic health, the C allele is associated with slightly lower fasting
glucose, offering a minor metabolic advantage, while the G allele may carry a
modest type 2 diabetes risk in certain populations.

Anti-inflammatory strategies — omega-3 fatty acids, adequate sleep, managing
chronic stress, and maintaining a diet rich in colourful vegetables and
polyphenols — are beneficial for all genotypes but especially important for
GG carriers with higher baseline inflammation.

Interactions

The -174G/C variant (rs1800795) is in strong linkage disequilibrium with
rs1800797 (-597G/A) in the same IL6 promoter region (r-squared = 0.92),
meaning these two variants are almost always inherited together. The nearby
rs1800796 (-572G/C) variant is an independent functional polymorphism that
can compound the effect on IL-6 levels, though it is primarily polymorphic
in East Asian populations. IL-6 signalling also interacts with the broader
inflammatory cascade — TNF-alpha and CRP levels are influenced by IL-6, so
this variant has downstream effects on systemic inflammation markers.